arrow
A

Abdulazeez Salawu

Mount Sinai Hospital
H指数:12
被引数:508

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Consensus Approach to the Incorporation of Total Neoadjuvant Therapy in a Treatment Algorithm for Stage I–III Resectable Rectal Cancer

针对I-III期可切除直肠癌治疗算法中纳入新辅助疗法的共识方法

2026-05-080
OAAI
Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic retroperitoneal sarcoma working group (TARPSWG)

多灶性和转移性腹膜后肉瘤的管理:大西洋两岸腹膜后肉瘤工作组(TARPSWG)更新的共识方法

2026-01-040
PRE
Access to clinical cancer genomics and precision oncology-based care in North America

北美临床癌症基因组学和精准肿瘤学护理的获取

2026-01-010
OAAI
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer
2024-09-012
PRE
Low-grade fi bromyxoid sarcoma and sclerosing epithelioid fi brosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group
2024-09-010
OAAI
Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada
2024-08-020
OAAI
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
2024-08-010
OA
Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
2023-10-211
OAAI
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Durvalumab联合奥拉帕利或西地尼布治疗晚期平滑肌肉瘤的安全性、免疫学和临床活性: DAPPER临床试验结果.

2023-08-115
PRE